Analyst Price Targets — ASTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 15, 2026 10:31 am | Michael Wiederhorn | Oppenheimer | $53.00 | $39.60 | TheFly | Astrana Health initiated with an Outperform at Oppenheimer |
| August 10, 2026 7:57 pm | — | Truist Financial | $55.00 | $37.47 | TheFly | Astrana Health price target raised to $55 from $47 at Truist |
| August 7, 2026 9:28 am | — | Barclays | $53.00 | $34.13 | TheFly | Astrana Health price target raised to $53 from $50 at Barclays |
| July 14, 2026 11:04 am | David Larsen | BTIG | $65.00 | $47.64 | TheFly | Astrana Health price target raised to $65 from $50 at BTIG |
| May 26, 2026 12:54 pm | — | Barclays | $50.00 | $39.00 | TheFly | Astrana Health upgraded to Overweight from Equal Weight at Barclays |
| May 14, 2026 1:25 pm | — | Truist Financial | $47.00 | $39.39 | TheFly | Astrana Health price target raised to $47 from $38 at Truist |
| May 11, 2026 9:21 am | — | Barclays | $37.00 | $39.30 | TheFly | Astrana Health price target raised to $37 from $26 at Barclays |
| May 8, 2026 1:53 pm | Matthew Shea | Needham | $41.00 | $37.90 | TheFly | Astrana Health price target raised to $41 from $30 at Needham |
| May 8, 2026 12:43 pm | — | Robert W. Baird | $45.00 | $36.03 | TheFly | Astrana Health price target raised to $45 from $40 at Baird |
| April 15, 2026 10:18 am | — | Robert W. Baird | $40.00 | $29.07 | TheFly | Astrana Health price target raised to $40 from $37 at Baird |
Latest News for ASTH
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. ("Astrana" or the "Company") (NASDAQ: ASTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. (“Astrana” or the “Company”) (NASDAQ: ASTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. ("Astrana" or the "Company") (NASDAQ: ASTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. (“Astrana” or the “Company”) (NASDAQ: ASTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
On October 09, 2026, Astrana Health Inc (ASTH) shares rose 4.7% to a current price of $37.55, within a 52-week range of $18.08 to $51.60. This movement reflects
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASTH.
U.S. House Trading
No House trades found for ASTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.